Calcium signaling: A therapeutic target to overcome resistance to therapies in cancer

Cell Calcium. 2022 Dec:108:102673. doi: 10.1016/j.ceca.2022.102673. Epub 2022 Nov 12.

Abstract

Innate and acquired resistances to therapeutic agents are responsible for the failure of cancer treatments. Due to the multifactorial nature of resistance, the identification of new therapeutic targets is required to improve cancer treatment. Calcium is a universal second messenger that regulates many cellular functions such as proliferation, migration, and survival. Calcium channels, pumps and exchangers tightly regulate the duration, location and magnitude of calcium signals. Many studies have implicated dysregulation of calcium signaling in several pathologies, including cancer. Abnormal calcium fluxes due to altered channel expression or activation contribute to carcinogenesis and promote tumor development. However, there is limited information on the role of calcium signaling in cancer resistance to therapeutic drugs. This review discusses the role of calcium signaling as a mediator of cancer resistance, and assesses the potential value of combining anticancer therapy with calcium signaling modulators to improve the effectiveness of current treatments.

Keywords: Calcium channels; Calcium signaling; Cancer; Chemoresistance; Potassium channels.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calcium
  • Calcium Channels
  • Calcium Signaling*
  • Carcinogenesis
  • Humans
  • Neoplasms* / drug therapy

Substances

  • Calcium
  • Calcium Channels